Orchard Therapeutics
A UK-based company developing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy.
In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy.
Latest Orchard Therapeutics News & Features
19 March 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze